Why would GlaxoSmithKline sell most of its cancer business to Novartis? In today's deal announcement, that particular sale stands up for questioning.
<div>
</div>
written on 22.04.2014
$16B deal for GlaxoSmithKline oncology meds turns Novartis into cancer heavyweight
